Morgan Barr

Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROADWAY): A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Underlying HeFH and/or Atherosclerotic Cardiovascular Disease Who are Not Adequately Controlled by Their Lipid-Modifying Therapies
Obicetrapib and Cardiovascular Outcomes: A Placebo-Contolled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10mg Obicetrapib in Participants with Athersclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally tolerated Lipid-Modifying Therapies. (Prevail)
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor Xia Inhibitor, Versus Apixaban in Participants with AF (LIBREXIA-AF)
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisirin on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)